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  Despite their popular use in breast augmentation and reconstruction 
surgeries, the limited biocompatibility of silicone implants can induce se-
vere side effects, including capsular contracture – an excessive foreign 
body reaction that forms a tight and hard fibrous capsule around the 
implant. This study examines the effects of using biomembrane-mimicking 
surface coatings to prevent capsular formations on silicone implants. The 
covalently attached biomembrane-mimicking polymer, poly(2-meth-
acryloyloxyethyl phosphorylcholine) (PMPC), prevented nonspecific protein 
adsorption and fibroblast adhesion on the silicone surface. More im-
portantly, in vivo capsule formations around PMPC-grafted silicone im-
plants in rats were significantly thinner and exhibited lower collagen 
densities and more regular collagen alignments than bare silicone 
implants. The observed decrease in α-smooth muscle actin also sup-
2
ported the alleviation of capsular formations by the bio-
membrane-mimicking coating. Decreases in inflammation related cells, 
myeloperoxidase and transforming growth factor-β resulted in reduced 
inflammation in the capsular tissue. The biomembrane-mimicking coatings 
used on these silicone implants demonstrate great potential for prevent-
ing capsular contracture and developing biocompatible materials for vari-
ous biomedical applications.
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1. Introduction
  Breast augmentation is the most common plastic surgery worldwide in 
2013 and occupies about 15% of all surgical cosmetic procedures [1]. 
Furthermore the number of cases continues to increase with society’s 
growing interest in beauty. In addition, demands for breast re-
construction surgery are increasing as a result of patients who have had 
mastectomies to remove cancerous tissues. Implants based on silicone 
elastomer bags that are filled with silicone gel, saline or other fillers are 
the most widely used implants for both breast augmentation and re-
constructive surgical procedures [2]. Recipients are generally well sat-
isfied with the breast-like mechanical properties and low cost of the sili-
cone-based breast implants, but limited biocompatibility still provokes se-
rious problems. Gabriel et al. [3] previously reported that, among 749 
women who had breast implantation, 208 (27.8%) had received revision 
surgery due to single or multiple complications. Among them, capsular 
contracture – serious fibrous capsule formation around implants – was 
the most frequent complication, causing 131 women (17.5%) to undergo 
further surgical intervention. It has been reported that capsular con-
tracture occurs over a time scale ranging from several months to years 
after breast implantation [4–7].
  It has been hypothesized that capsular contracture might result from 
excessive foreign body reactions on the silicone surface, gel bleed, dust, 
glove powder, etc., or by subclinical infection by normal skin flora 
(usually by Staphylococcus epidermidis) [8–12]. The foreign body reaction 
include, in particular, the inflammatory process and exaggerated scar re-
sponse to a foreign prosthetic material [13,14]. Here, a fibrous capsule 
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develops around the implant by the natural healing response to the 
presence of a foreign body, but results in excessive fibrotic scarring. 
Although the mechanism has not yet been elucidated in detail, the for-
eign body reaction is likely initiated by non-specific adsorption of pro-
teins on the silicone surface within several minutes of implantation [15]. 
Macrophages are then recruited to the implantation site and form giant 
cells within 2 days due to their inability to successfully phagocytose the 
too-large foreign body. Collagenous encapsulation and excessive for-
mation of fibrous tissue around the implant occur within 3 weeks.
  Surface modifications of silicone implants have been studied as a 
means of reducing excessive foreign body reactions. Silicone implants 
coated with polyurethane [16] or fabricated with textured surfaces [17] 
have demonstrated limited success in clinical studies. However, the prev-
alence of capsular contracture after implantation remains significantly 
high [18], so the search for more biocompatible surfaces continues.
  Among the various methods used to prepare biocompatible surfaces, 
coating with biomembrane-mimicking materials is very attractive [19]. 
Poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) mimics the head 
group of phosphatidylcholine in the cell membrane and exhibits excep-
tional anti-protein-adsorption activity, anti-thrombotic activity and hemo-
compatibility when used in coating materials for coronary stents [20], ar-
tificial joints [21], drug delivery carriers [22] and biomicrofluidics [23]. 
Increased hydrophilicity due to zwitterionic groups and bio-
membrane-mimicking phosphorylcholine moieties of PMPC are important 
contributors to the outstanding biocompatibility exhibited by PMPC-coat-
ed materials [24].
  The present study examines the effects of PMPC coating on capsular
formation around silicone implants inserted into rats (Fig. 1). Although 
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implants coated with other polymers, including hyaluronic acid (HA), pol-
yethyleneglycol (PEG) and polyacrylamide (PAAm) [25], failed to alleviate 
capsular formation, I suspected that, given its biomembrane-mimicking 
properties, PMPC-coated silicone implants have the potential to modulate 
the initiation process and to reduce excessive capsular formation. It has 
been previously reported that the surface of polydimethylsiloxane 
(PDMS), a silicone elastomer, was successfully coated by PMPC, resulting 
in significantly reduced protein adsorption and cell adhesion [26,27]. In 
this study, successful PMPC coating of the silicone implants was con-
firmed via dynamic water contact angles and X-ray photoelectron spec-
troscopy (XPS). Subsequently, nonspecific protein adsorption and the ad-
hesion of fibroblast cells, which were the primary collagen-producing 
cells, were measured. More importantly, PMPC-coated silicone implants 
were inserted subcutaneously into the backs of rats, and the resulting 
capsular formations were carefully compared to those observed on bare 
silicone implants. Various quantitative studies comparing capsular thick-
ness, inflammatory cells, vascularity and amounts of transforming growth 
factor-β (TGF-β), α-smooth muscle actin, myeloperoxidase and CD34 were 
performed to examine the effects of PMPC coating on capsular 
formation. 
  In vivo analysis of PMPC-coated silicone implants is very important for 
finding ways to reduce the side effects of implantation, including capsu-
lar contracture, through a greater understanding of the mechanisms of 
foreign body reactions, and is crucial for establishing strategic footholds 
regarding the use of biocompatible materials in various biomedical 
applications.
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2. Materials and methods
2.1. Materials
  PDMS elastomer base and curing agent (Sylgard 184) were purchased 
from Dow Corning (USA). Benzophenone, bovine serum albumin (BSA) 
and bovine plasma fibrinogen (BPF) were purchased from Sigma-Aldrich 
(USA). 2-Methacryloyloxyethyl phosphorylcholine (MPC) monomer was 
purchased from KCI (Korea). Dulbecco’s modified Eagle’s medium 
(DMEM), Dulbecco’s phosphate buffered saline (DPBS) and fetal bovine 
serum (FBS) were purchased from WelGENE (USA).
2.2. Preparation of silicone implants
  The silicone implants were prepared from the silicone elastomer 
(PDMS) base (Sylgard 184) according to the manufacturer’s protocol. A 
mixture of the base and the curing agent (10:1, w/w) was poured on a 
glass plate, degassed in a vacuum chamber and cured in an oven at 100 
ºC for 1 h. The cured silicone plate was cut into a disk (15 mm diame-
ter, 0.5 mm thickness for in vitro and 2 mm thickness for in vivo) and 
preserved in acetone.
2.3. PMPC coating on the silicone implants
  The silicone implant was covalently coated with PMPC according to 
the method in the previous report [26]. The silicone implant was dipped 
into acetone-dissolved benzophenone (10 mg ml–1) for 1 min. After dry-
ing in a vacuum chamber for 1 h, the benzophenone-adsorbed silicone 
implant was immersed in aqueous solutions containing various MPC mon-
omer concentrations. The silicone implant was irradiated by UV from a 
8
500W high-pressure mercury lamp (MS UV, Korea) for 15 min. Unreacted 
monomers, benzopinacol and excess benzophenone were removed by 
thorough washing with acetone and water. Finally, the coated silicone 
implant was soaked with water overnight to remove any remaining ace-
tone and non-covalently attached polymers.
2.4. Measurement of the water contact angle
  Dynamic water contact angles were measured to examine the hydro-
philicity of the implant surfaces. Advancing contact angles were meas-
ured as the water volume was increased from 0 to 6 μl, whereas reced-
ing contact angles were measured as the water volume was decreased 
from 6 to 3 μl.
2.5. X-ray photoelectron spectroscopy (XPS)
  Surface elemental analysis of the bare silicone implant and the 
PMPC-coated silicone implant was performed using XPS. The XPS instru-
ment (AXIS-HIS, Kratos-Shimadzu) used an X-ray source of Mg Kα (15 kV) 
in a Mg/Al dual anode. The X-ray detector was located at a position 45º 
away from the normal. Each plate was cut into a 7 mm × 7 mm square 
and examined for C1s, O1s, Si2p, N1s and P2p.
2.6. Protein adsorption assay
  BSA (4.5 mg ml–1) and BPF (0.3 mg ml–1) were dissolved in DPBS. 
Each silicone implant was incubated in the protein solution on an orbital 
shaker (200 rpm) at 37 ºC for 1 h. After washing twice with fresh DPBS, 
the amount of adsorbed protein was quantified using a Micro™ BCA 
protein assay kit (Thermo Scientific). The absorbance at 570 nm was 
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measured using a spectrophotometer (V-650, Jasco).
2.7. Cell adhesion test
NIH 3T3 (mouse fibroblasts) cells were seeded on the silicone blocks in 
24-well tissue culture dishes at 30,000 cells per well in 1 ml of DMEM 
containing 10% FBS. After incubation at 37 ºC for 40 h, cells were gently 
washed with fresh DMEM containing 10% FBS. The adhered cells on the 
silicone implant were quantified using a cell counting kit (CCK, Dojindo).
2.8. Preparation of animals
  Twenty female Sprague-Dawley rats, aged 8 weeks with an average 
body weight of approximately 250 g at the time of implantation, were 
used to evaluate capsular formation on the silicone blocks in vivo. All 
animals were free of specific pathogens and were maintained under the 
same food and environmental conditions. After an adaptation period of 1 
week, healthy animals were selected for the experiment. The rats were 
housed in an animal facility and treated in accordance with the Guide 
for the Care and Use of Laboratory Animals of Seoul National University 
Hospital. This study was approved by the Institutional Animal Care and 
Use Committee (IACUC) of the Seoul National University Hospital (IACUC 
No. 11-0383).
2.9. Insertion of the silicone implants
  All surgical procedures were performed by the same individual (J.U.P.). 
The surgical field was prepared using 10% povidone-iodine, and a single 
dose of cefazolin (60 mg kg–1) was administered intramuscularly for pro-
phylaxis against infection. The animals were anesthetized using an intra-
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peritoneal injection of Zoletil® (30 mg kg–1) and Rumpun® (5 mg kg–1). 
The two pockets for implant insertion were made at the back of each 
rat through two separate 2 cm vertical incisions, which were started at 
the lateral point 1.5 cm outside the midline and 1 cm below the should-
er bone (Fig. 6A). PDMS and PMPC–PDMS (coated using an MPC con-
centration of 0.50 M) (Fig. 6B) were implanted beneath the panniculus 
carnosus muscle. PDMS was positioned in the left back pocket and 
PMPC–PDMS was positioned in the right side pocket. Twenty replicates 
(10 for a 4-week analysis and 10 for a 12-week analysis) of each sample 
type were implanted. Muscle and skin incisions were closed using 4-0 
Vicryl® and 5-0 Ethilon® sutures (Ethicon, Inc., USA).
2.10. Harvest of capsule from embedded silicone implants
  After 4 or 12 weeks, the rats were sacrificed using CO2 asphyxiation in 
accordance with AVMA (American Veterinary Medical Association) 
Guidelines for the Euthanasia of Animals. The capsular tissue formed 
near the implanted silicone implant was retrieved through a skin incision 
(Fig. 6C). The fibrous capsule around the silicone implant underwent 
gross examination before being harvested from the central portions of 
the upper and lower surfaces of the implant.
2.11. Histological analysis
  Harvested specimens were fixed in 10% formalin. After 24 h, each 
specimen was embedded in paraffin and sections were cut transversely 
to visualize the architecture of the capsule. Histological analysis was per-
formed using hematoxylin and eosin (H&E) staining. Each stained slide 
was examined at ×100 magnification using a Leica DM2500 microscope 
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(Leica Microsystems-Switzerland Ltd, Switzerland), and images were cap-
tured from three microscopic fields: right, center and left. The capsular 
thickness was measured at the maximal point using National Institutes 
of Health Image J 1.36b imaging software (National Institutes of Health, 
Bethesda, MD, USA). Next, the cellularity and vascularity were examined 
in each image. The number of cells per unit area (0.01 mm2) was calcu-
lated automatically by the LAS Core Image Program (Leica Application 
Suite software, version 2.4.0, Leica Imaging Systems Ltd, Cambridge UK). 
The number of blood vessels per unit area (1 mm2) was counted man-
ually for each image and expressed as a vessel number.
  Immunohistochemical staining was performed using rabbit anti-TGF-β 
(1:100; Abcam, UK), mouse anti-α-smooth muscle actin (1:200; DAKO, 
USA), rabbit anti-myeloperoxidase (1:300; DAKO, USA) and mouse an-
ti-CD34 (1:500; Santa Cruz Biotechnology, USA) antibodies. After endoge-
nous peroxidase quenching, the antigens were retrieved at high temper-
ature (citrate buffer, pH 6.0). The slides were processed using Vectastain 
Elite ABC reagent (Vector Laboratories, USA) according to the manu-
facturer’s instructions. After treatment with the appropriate biotinylated 
secondary antibody, sections were developed with 3,3-diaminobenzidine 
(DakoCytomation, Denmark) in chromogen solution and counter-stained 
with Harris’s hematoxylin. Immunohistochemical staining was evaluated in 
three areas, as with H&E staining. The total pixel intensity was meas-
ured using Leica Q win image program V 3.2.0 (Leica Imaging Systems 
Ltd), and data were expressed as optical densities.
2.12. Statistical analysis
  All data are expressed as means ± SEM (standard error of the mean). 
Data analysis was performed using GraphPad Prism (version 6.00 for 
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Windows, GraphPad Software, La Jolla, CA, USA). For all data, significant 
differences were determined using an unpaired t-test, assuming Gaussian 
distribution and that both populations have the same standard 
deviations. The accepted level of significant difference for the test was 
p < 0.05, and the degree of difference is indicated on the graph as 
****, ***, ** and * for p < 0.0001, 0.0001 ≤ p < 0.001, 0.001 ≤ p < 




3.1. Surface coating of silicone implants with PMPC
  UV-induced radical polymerization was used to covalently coat PMPC 
on the silicone surface, following the methodology of the previous re-
port (Fig. 2) [26]. PDMS blocks were used as model silicone implants. 
Benzophenone was adsorbed on the surface of the PDMS as a photo-
sensitizer, and the implant was irradiated with UV while in the MPC 
monomer solution. Benzophenone radicals were first formed by UV irra-
diation at a wavelength near 365 nm, and methylene radicals were suc-
cessively formed on the PDMS surface. MPC monomers were poly-
merized on the surface, and PMPC-grafted silicone implants were ob-
tained using varying initial concentrations of MPC (0.10, 0.25 and 0.50 
M).
  Measurements of water contact angles supported the formation of 
PMPC grafts on the silicone implants (Fig. 3). As the concentration of 
MPC monomer was increased, the water contact angle decreased, in-
dicating increasing surface hydrophilicity. The advancing contact angle 
changed from 108º (Noncoated) to 81º (0.50 M MPC), and the receding 
contact angle changed from 88º (Noncoated) to 38º (0.50 M MPC). As 
zwitterionic phosphorylcholine residues of PMPC are more hydrophilic 
than methyl residues of PDMS, the measured increase in hydrophilicity 
supported successful coating of PMPC on the PDMS surface.
  The existence of a PMPC graft on the silicone implant was also con-
firmed using XPS (Fig. 4). The range of binding energies was selected 
for the detection of carbon, oxygen, silicone, nitrogen and phosphorus. 
The presence of nitrogen and phosphorus signals and the reduction of 
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silicone signals in PMPC–PDMS (coated PDMS in an MPC concentration 
of 0.50 M) provided evidence that the PDMS surface was covered by 
phosphorylcholine moieties. In addition, the PDMS surface showed a car-
bon peak at the C1s binding energy for only methylene (-CH2-) or methyl 
(-CH3) groups, whereas the PMPC–PDMS sample showed two other 
peaks at the C1s binding energies for a carbon–oxygen single bond 
(-C-O-) and a double bond (-C=O). Moreover, a shoulder O1s peak could 
be observed in PMPC–PDMS, providing evidence of carbon–oxygen 
bonds in PMPC. Both water-contact-angle data and XPS spectra strongly 
support the successful introduction of PMPC to silicone implants using 
UV-induced polymerization.
3.2. In vitro protein adsorption and cell adhesion test
  It was previously reported that PMPC-coated PDMS could prevent 
non-specific protein adsorption on the silicone surface [26]. Similarly, I 
analyzed the adsorption of albumin and fibrinogen, two of the most 
abundant proteins in serum. As shown in Fig. 5A, PMPC–PDMS exhibited 
adsorptions of BSA and BPF reduced by 52 and 63%, respectively, com-
pared to PDMS. Fig. 5B shows the adhesion of mouse fibroblast cells 
(NIH-3T3) observed on the silicone implants. It is clear that the PMPC 
coating can prevent the adhesion of fibroblasts.
3.3. In vivo capsular formation
  After it was confirmed that protein adsorption and cell adhesion on 
silicone implants were inhibited by PMPC coating, Implantations for 
PDMS and PMPC–PDMS beneath the panniculus carnosus muscle on the 
back of rats were conducted so that I could observe capsular formation 
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around the implants (Fig. 6). After 4 or 12 weeks, tissues around the sil-
icone implants were carefully obtained in order to compare capsular 
formations.
  First, I compared the capsular thickness around PDMS and PMPC–
PDMS. Histological estimation of the peri-implant capsular thickness 
showed significant differences between PDMS and PMPC–PDMS at both 
time points (Fig. 7). The capsules around PDMS were significantly thicker 
than those around PMPC–PDMS. After 4 weeks, the average capsular 
thicknesses were 369 μm in the PMPC–PDMS group and 509 μm in the 
PDMS group. After 12 weeks, the capsular thicknesses were 207 and 247 
μm, respectively. Upon gross examination, the tissues around the PMPC–
PDMS implant demonstrated a more parallel arrangement of collagen fi-
bers and lower collagen density compared to the tissues around the 
PDMS implant, which showed a denser, more irregular collagen-fiber ar-
rangement at each of the two time points.
  In addition, investigating capsular formation based on the contact site 
of the implant, I compared capsular thicknesses on the superficial and 
deep surfaces of the silicone implants. In all groups, no remarkable dif-
ferences in capsular thickness were observed between superficial and 
deep sections (Fig. 8).
3.4. Cellularity and vascularity
  Inflammatory cells, such as neutrophils and macrophages, act as major 
mediators in inflammatory reactions by secreting various cytokines, re-
cruiting fibroblasts and activating collagen synthesis, resulting in capsule 
formation. Estimation of the numbers of intracapsular inflammatory cells 
was conducted using the LAS Image Analysis Program (Fig. 9A). At the 
4-week point, the PDMS group (52 counts per unit area) showed sig-
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nificantly higher numbers of inflammatory cells than the PMPC–PDMS 
group (41 counts per unit area). After 12 weeks, the PDMS group (29 
counts per unit area) also exhibited a significantly higher count than the 
PMPC–PDMS group (24 counts per unit area). The inflammatory cell 
counts were in accordance with the capsular thickness results. The high-
er numbers of inflammatory cells observed in the non-coated PDMS 
group were directly related to thick capsular formations at both time 
points.
  I also compared the vascularity of capsular tissues around the silicone 
implants. There were no significant differences between the PDMS group 
and the PMPC–PDMS group at either time point, although the PDMS 
group showed slightly higher vascular numbers than the PMPC–PDMS 
group (Fig. 9B). 
3.5. Immunohistochemistry analysis in capsular formation
  I performed immunohistochemistry (IHC) to obtain a more detailed 
analysis of the capsular formation around our silicone implants (Figs. 
10-13). Transforming growth factor-β (TGF-β) is a main growth factor se-
creted from inflammatory cells and functions in fibroblast chemotaxis, 
activation of extracellular matrix deposition, increased collagen synthesis 
and down-regulation of matrix metalloproteinases. At the 4-week point, 
the optical density of TGF-β in the PDMS group (mean optical density; 
2.05) was significantly higher than that in the PMPC–PDMS group (mean 
optical density; 1.05) (Fig. 10), providing evidence (in addition to the re-
sults obtained for capsular thickness and cellularity) of a more severe in-
flammatory reaction against PDMS than against PMPC–PDMS. At the 
12-week point, the PDMS group demonstrated a mean optical density of 
1.30, compared to 0.857 for the PMPC–PDMS group. Although the differ-
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ence is not significant, the optical density of the PDMS group was still 
higher than that of the PMPC–PDMS group. I expected that the low tit-
er of TGF-β on the surface of PMPC-coated silicone implants would con-
tribute to the down-regulation of inflammation and the suppression of 
capsular formation. 
  Regarding α-smooth muscle actin as a sign of the formation of myofi-
broblasts, I did not observe any difference between the PDMS group 
(mean = 1.54) and the PMPC–PDMS group (mean = 1.41) at the 4-week 
point. In contrast, at 12 weeks, the PMPC–PDMS group (mean = 1.44) 
showed a significantly lower level of α-smooth muscle actin than the 
PDMS group (mean = 2.21) (Fig. 11).
  Myeloperoxidase levels could also be used to approximately quantify 
local inflammatory reactions. At both time points, the PMPC–PDMS 
group showed a significantly lower level of myeloperoxidase than the 
PDMS group (Fig. 12). The low myeloperoxidase level in the PMPC–PDMS 
group indicates a reduced inflammatory reaction with less capsular tissue 
formation.
  The vascularity of capsular tissues around each silicone implant was 
further confirmed by IHC using an anti-CD34 antibody as the marker of 
endothelial cells. At both time points, I observed no significant differ-
ence in CD34 levels between the PDMS group and the PMPC–PDMS 
group (Fig. 13). These results are further supported by the lack of vascu-
larity differences observed via H&E staining (Fig. 9B).
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4. Discussion
  Although the cause and exact mechanism of capsular contracture are 
still controversial, I hypothesized that the reduction of excess foreign 
body reactions is one of the key factors to alleviate the capsular 
contracture. It was expected that the surface modification of silicone im-
plants with a biomembrane-mimicking polymer, PMPC, can suppress the 
induction of the excess foreign body reaction due to its resemblance to 
cell surfaces.
  Various methods, including oxidation, non-covalent adsorption and co-
valent grafting, have been used for the surface modification of silicone. 
Most of the methods introduced hydrophilic surfaces on silicone. 
Oxidation through oxygen plasma or water vapor plasma treatment was 
shown to produce hydroxyl groups (-OH) on the PDMS surface tempora-
rily [28] or semi-permanently [29]. A solvent vaporization method [30] 
and simple dipping or swelling of PDMS platforms in polymeric solutions 
[31,32] have also been used for non-covalent modifications. In this study, 
I selected the covalent grafting method because it produces a modified 
surface with the highest durability for semi-permanent use of silicone im-
plants in the body.
  As shown in Fig. 3, hydrophilicity was clearly increased in PMPC-coated 
surfaces. Adsorption of albumin and fibrinogen was successfully pre-
vented and adhesion of fibroblasts was significantly inhibited by the 
PMPC coating. Given that protein adsorption is considered to be the 
first step in the foreign body reaction and that fibroblasts play an im-
portant role in capsular formation [15], PMPC-coated silicone implants 
were expected to be able to alleviate excessive capsular formation. 
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Although PMPC coating produced hydrophilic surfaces similar to other 
methods, the resulting surfaces have a different tendency to adhesion of 
cells. Hydroxyl-group-modified silicone surfaces exhibited enhanced adhe-
sion of fibroblasts as the hydrophilicity increased [33]. The attachment 
of fibroblasts was facilitated even more on the amine-group- or carbox-
ylic-acid-group-modified surfaces compared to the hydroxyl-group-modified 
surfaces [34]. However, the PMPC-coated surfaces with zwitterionic phos-
phorylcholine groups showed dramatically reduced adhesion of fibroblasts 
regardless of the surface charges [35], which represents the different 
characteristics of the biomembrane-mimicking PMPC-coated surfaces.
  When the implant was inserted in vivo, a foreign body reaction was 
triggered, leading to a cascade of inflammatory cell recruitment, fibro-
blast proliferation, collagen synthesis and capsular formation. A stronger 
foreign body reaction leads to more excessive capsular formation, such 
that the capsular thickness and density and the collagen regularity can 
provide a road map regarding foreign body reactions against implanted 
materials. Moreover, capsular thickness is positively related to the occur-
rence of capsular contracture [36]. The capsular thickness decreased dur-
ing the period between 4 and 12 weeks in the PDMS and PMPC–PDMS 
groups (Fig. 7). In addition, PMPC-coated silicone implants resulted in 
less excessive extracellular matrix formation than uncoated silicone 
implants. Considering that the capsular contracture normally proceeds 
through 1 year [6], the analyses at the 4- and 12-week points are rela-
tively short, but the initial process of capsular formation can be ob-
served in this model system. I supposed that a proliferation phase was 
activated after the inflammatory phase, resulting in vigorous collagen 
production and accumulation at 4 weeks, and that collagen maturation 
and rearrangement mainly occurred at 12 weeks. This short-term trend 
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had also been reported in a previous article [36]. Given the similarity in 
decreased capsular thicknesses observed for the PDMS and PMPC–PDMS 
groups (51% decrease for PDMS and 44% decrease for PMPC–PDMS dur-
ing 8 weeks), I expected that the overall durations of the respective 
foreign body reaction procedures were also likely to be similar.
  Many pieces of evidence for the course of capsular formation 
(inflammation, fibroblast proliferation, and then capsule formation and 
maturation) were also found in the cellularity and IHC analyses (Figs. 
9-13). The PMPC–PDMS group clearly showed lower numbers of in-
flammatory cells (Fig. 9A) and smaller amounts of inflammatory markers 
such as TGF-β and myeloperoxidase (Figs. 10 and 12) than the PDMS 
group, which strongly supported the reduction of inflammation around 
the PMPC-coated implants at both time points.
  The number of inflammatory cells and the amount of TGF-β and mye-
loperoxidase were decreased during the period between 4 and 12 weeks. 
Thus, I supposed that the most relevant event occurring at the 4-week 
point was the inflammatory cell response, including the migration of in-
flammatory cells and the release of cytokines. There were then sig-
nificant decreases in inflammatory cell number and myeloperoxidase 
amount from 4 to 12 weeks. These decreases may reflect the transition 
from the inflammatory and proliferation phase to the maturation phase. 
At the 12-week point, the formation of an extracellular matrix by myofi-
broblasts and collagen maturation may be the most relevant events in 
the peri-implant tissue, which showed an increased level of α-smooth 
muscle actin (Fig. 11).
  The correlation between vascularity and capsular formation is the sub-
ject of controversy. In this study both the vascularity and CD34 data 
showed no differences between PDMS and PMPC–PDMS, and between 4 
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and 12 weeks (Figs. 9B and 13). In a clinical study, Rubino et al. and 
Wynn et al. reported that capsules without contracture were thinner and 
less vascularized than those with contracture and suggested that vascula-
rization could facilitate the development and growth of contracture cap-
sules [37,38]. However, Vieira et al. reported that more vascularized tis-
sue resulted in a softer capsule and a lower probability of capsular con-
tracture in breast augmentation [36]. More research is required to de-
termine the relationship between neoangiogenesis and capsular formation
in implantations.
  A previous study using silicone implants coated with other hydrophilic 
polymers, such as PEG, HA and PAAm, failed to alleviate capsular for-
mation [25]. Hydroxylated silicone implants showed a similar decrease in 
capsular thickness with PMPC-coated silicone implants in this study, but 
the inflammation score was not different from that of the untreated sili-
cone [39]. Plasma- and collagen-coated silicones enhanced adhesion of 
cells and increased angiogenesis in peri-implant tissues [40]. In another 
study, silicone implants thickly coated with a spider silk protein (eADF4) 
showed a similar reduction in both capsular formation and inflammation 
with PMPC-coated silicone implants [41]; however, eADF4 has the draw-
backs of being somewhat unstable and expensive [42]. 
  The comparison of in vivo results of capsular formation using diverse 
treatments is actually not very simple because each study has many vari-
ables, like types of implant, kinds of animal, and types of implantation 
site. In order to attribute more definite effects to capsular contracture, 
long-term in vivo tests, including the measurement of actual pressure 
upon miniaturized fluidic hemisphere-shaped silicone implants inserted be-
neath the breast of larger animals rather than solid plate-shaped ones 
inserted in the backs of rats, will be necessary. However, the silicone 
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implants semi-permanently coated with the biomembrane-mimicking poly-
mer PMPC, which showed significant alleviation of capsular formation 
and excessive inflammation in this study, have good potential as a plat-




In the present study, I covalently coated silicone implants with a bio-
membrane-mimicking polymer, PMPC, and confirmed a reduction in the 
adhesion of proteins and fibroblasts and in vivo peri-implant capsular 
formation through 12 weeks experiments. PMPC-coated silicone implants 
showed a significant decrease in capsular thickness compared to 
non-coated implants. The accompanying decrease in inflammation-related 
cells, TGF-β and myeloperoxidase strongly supported the reduction of in-
flammation in the tissues surrounding the implants. Moreover, significant 
decreases in α-smooth muscle actin and collagen density around the 
PMPC-coated implants also supported the alleviation of capsular for-
mation by the biomembrane-mimicking coating. Although longer-term 
analysis will be required, the biomembrane-mimicking coating could well 
be a foothold for suppressing breast capsular contracture as well as un-
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Fig. 1. Schematic illustration of silicone-implant coating and implantation. 
(A) Biomembrane-mimicking PMPC, a hydrophilic and biocompatible poly-
mer containing the head group of the most abundant phospholipid in 
cell membranes. (B) Preparation of PMPC–PDMS via UV-induced surface 
polymerization of MPC on PDMS. (C) In vivo comparison, for the pur-
pose of examining biocompatibility, of capsules formed on PDMS and 
PMPC–PDMS in rats.
30
Fig. 2. Preparation of PMPC–PDMS. (A) Physical adsorption of benzophe-
none (BP). (B) Initiation of polymerization. (C) Formation of PMPC-graft-
ed PDMS.
31
Fig. 3. Water contact angle based on MPC concentration. Data are rep-
resented as mean ± SEM (n = 18).
32
Fig. 4. XPS data obtained for PDMS and PMPC–PDMS (coated using an 
MPC concentration of 0.50 M).
33
Fig. 5. In vitro protein adsorption and cell adhesion onto PDMS and 
PMPC–PDMS (MPC concentration = 0.50 M). (A) Relative amounts of ad-
sorbed BSA and BPF. (B) Relative amounts of adhered mouse fibroblasts 
(NIH-3T3). Data are represented as means ± SEM (n = 3). The marker 
(*) indicates 0.01 ≤ p < 0.05.
34
Fig. 6. In vivo experiment to investigate capsular formation on PDMS 
and PMPC–PDMS (MPC concentration = 0.50 M) using a rat model. (A) 
Insertion of silicone implants in the back of each rat. On the third im-
age from the left, the dashed circle indicates the PDMS plate. (B) PDMS 
and PMPC–PDMS silicone implants. (C) Harvest of silicone implants from 
rats sacrificed after 4 or 12 weeks. An arrow indicates the plate-lying 
side in the 12-week image. The small images depict the representative 
shapes of capsules around the silicone implants.
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Fig. 7. Capsular thicknesses around the PDMS and PMPC–PDMS implants 
after 4 and 12 weeks in rats. (A) H&E staining images. The region of 
each capsule was indicated with an arrow. (B) Thickness of the capsule 
formed after 4 weeks and 12 weeks (n = 60). Data are represented as 
means ± SEM. The markers (****) and (**) indicate p < 0.0001 and 
0.001 ≤ p < 0.01, respectively.
36
Fig. 8. Comparison of capsular thicknesses measured at superficial and 
deep surface levels. Data are indicated as means ± S.E.M (n=30). The 
marker (*) indicates 0.01 ≤ p < 0.05.
37
Fig. 9. In vivo analysis of intracapsular inflammatory cells and vascular 
formations. (A) The number of inflammatory cells (n = 60) and (B) the 
number of developed vessels (n = 60). Data are represented as means ± 
SEM. The marker (*) indicates 0.01 ≤ p < 0.05. ‘‘No SD’’ means there 
is no significant difference.
38
Fig. 10. Analysis for TGF-β using in vivo IHC analysis of tissues surround-
ing the PDMS and PMPC–PDMS implants. (A) Representative IHC images 
indicating amount of TGF-β (brown) as the key landmark of an in-
flammatory reaction. (B) Amount of TGF-β measured by optical densities. 
Data are indicated as means ± SEM (n = 20). The marker (**) indicates 
0.001 ≤ p < 0.01. ‘‘No SD’’ means there is no significant difference. 
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Fig. 11. Analysis for α-smooth muscle actin using in vivo IHC analysis of 
tissues surrounding the PDMS and PMPC–PDMS implants. (A) 
Representative IHC images indicating amount of α-smooth muscle actin 
(brown). The fibrous capsular layer of spindle-like and α-smooth muscle 
actin-containing cells is shown. (B) Amount of α-smooth muscle actin 
measured by optical densities. Data are indicated as means ± SEM (n = 
20, but n = 18 for 4-week data). The marker (**) indicates 0.001 ≤ p < 
0.01. ‘‘No SD’’ means there is no significant difference. 
40
Fig. 12. Analysis for myeloperoxidase using in vivo IHC analysis of tissues 
surrounding the PDMS and PMPC–PDMS implants. (A) Representative IHC 
images indicating amount of myeloperoxidase (brown), which was mainly 
expressed in inflammatory cells such as neutrophils. (B) Amount of α
-smooth muscle actin measured by optical densities. Data are indicated 
as means ± SEM (n = 20). The marker (**) indicates 0.001 ≤ p < 0.01. 
41
Fig. 13. Analysis for CD34 using in vivo IHC analysis of tissues surround-
ing the PDMS and PMPC–PDMS implants. (A) Representative IHC images 
indicating CD34 (brown)-stained endothelial cells. (B) Amount of α
-smooth muscle actin measured by optical densities. Data are indicated 




  유방 확대술과 재건술이 널리 시술되고 있으며 그 수요가 날로 증가하
는 반면 이에 쓰이는 실리콘 보형물의 낮은 생체적합성은 환자들에게 고
통스러운 부작용을 가져다준다. 가장 널리 알려진 부작용 중 하나는 구형 
구축 (capsular contracture)이며 이는 과도한 이물 반응 (foreign body 
reaction)에 의해 보형물에 딱딱하고 두꺼운 섬유 조직이 캡슐로 둘러싸게 
되면서 발생한다. 본 연구는 실리콘 보형물 위의 과도한 섬유 조직 형성을 
막기 위해 생체막 모방 고분자를 이용해 보형물의 표면을 코팅하는 것이 
주목적이다. 실리콘 보형물의 표면에 공유결합으로 강하게 결합된 고분자 
PMPC (Poly(2-methacryloyloxyethyl phosphorylcholine))는 실리콘 표면의 
단백질 흡착과 섬유아세포 점착을 막아준다. 또한 쥐 (rats)의 등 (back) 
피하에 삽입된 PMPC로 코팅된 실리콘 보형물은 일반 실리콘 보형물에 비
해 현저히 얇은 캡슐을 형성하는 것을 확인했으며, 생성된 캡슐 속의 콜라
겐의 밀도가 더욱 낮고 잘 정렬되어 있는 것을 확인할 수 있었다. 또한 코
팅된 실리콘에서 α-smooth muscle actin이 훨씬 적은 양이 존재한다는 점
이 캡슐 형성이 완화되었다는 증거를 보충해준다. 뿐만 아니라, 코팅된 실
리콘에서의 염증세포 수의 감소, myeloperoxidase 양의 감소,  
transforming growth factor-β의 감소는 염증반응 또한 적게 일어났음을 
보여준다. 이러한 생체막 모방 고분자를 이용한 실리콘 보형물의 코팅은 
구형 구축을 막을 수 있는 실현가능한 대안을 제시하고 있으며 다른 생체·
의학적 적용을 위한 생체에 적합한 물질을 만드는 데에도 널리 쓰일 수 
있을 것이라고 예상한다.
주요어: 실리콘 보형물, 구형 구축, PMPC, 표면 개질, 이물 반응
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